NASDAQ : BBTX

Bambusa Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.

Details

NameBambusa Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Founded2024
Ipo Date2026-10-30
CeoShanshan Xu
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price16.00
Cik2044950
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Shanshan Xu, M.D., Ph.D., M.B.A.Co-Founder, Chief Executive Officer, President, and Chairperson
Jonathan I. Lieber, M.B.A.Chief Financial Officer
Thang Ho, Ph.D.Co-Founder and Chief Development Officer
Crystal MacKayChief Operating Officer
Derek DiRocco, Ph.D.Director
Christian Foerster, M.Sc.Director
Helmut Jeggle, M.B.A.Co-Founder and Director
Howard Liang, Ph.D., M.B.A.Lead Independent Director

Contact

Address22 Boston Wharf Road, Floor 7, Boston, Massachusetts 02210, United States
Phone(617) 848-6188
Websitehttps://www.bambusatx.com